PODD Jul 2025 170.000 put
| Previous close | 27.38 |
| Open | N/A |
| Bid | 12.90 |
| Ask | 19.20 |
| Strike | 170.00 |
| Expiry date | 2025-07-18 |
| Day's range | 27.38 - 27.38 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Business WireInsulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
ACTON, Mass., June 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin del
Business WireInsulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
ACTON, Mass., June 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as
GuruFocus.comInsider Sale at Insulet Corp (PODD) by SVP & Chief Technology Officer Mark Field
On June 14, 2024, Mark Field, Senior Vice President & Chief Technology Officer of Insulet Corp (NASDAQ:PODD), executed a sale of 1,500 shares of the company.
